CYCLIC NITRONE FREE-RADICAL TRAPS - ISOLATION, IDENTIFICATION, AND SYNTHESIS OF 3,3-DIMETHYL-3,4-DIHYDROISOQUINOLIN-4-OL N-OXIDE, A METABOLITE WITH REDUCED SIDE-EFFECTS
Ce. Thomas et al., CYCLIC NITRONE FREE-RADICAL TRAPS - ISOLATION, IDENTIFICATION, AND SYNTHESIS OF 3,3-DIMETHYL-3,4-DIHYDROISOQUINOLIN-4-OL N-OXIDE, A METABOLITE WITH REDUCED SIDE-EFFECTS, Journal of medicinal chemistry, 39(25), 1996, pp. 4997-5004
A C-4 hydroxylated metabolite (2, 3,3-dimethyl-3,4-dihydroisoquinolin-
4-ol N-oxide) of the previously described cyclic nitrone free radical
trap 1 (3,3-dimethyl-3, 4-dihydroisoquinoline N-oxide, a cyclic analog
of phenyl-tert-butylnitrone (PBN)) was isolated, identified, and synt
hesized. The metabolite (2), though a less potent antioxidant than 1 i
n an in vitro lipid peroxidation assay, showed greatly reduced acute t
oxicity and sedative properties. Several analogs of 2 were prepared in
attempts to improve on its weak antioxidant activity while retaining
the desirable side effect profile. Effective structural changes includ
ed replacement of the gem-dimethyl moiety with spirocycloalkane groups
and/or oxidation of the alcohols to the corresponding ketones. All of
the analogs were more lipophilic (log K'(w)) and more active in the s
tandard lipid peroxidation assay than 2. In addition, some of the comp
ounds were able to protect cerebellar granule cells against oxidative
damage (an in vitro model of oxidative brain injury) with IC50 values
well below the value of the lead compound 1. The ketones, as predicted
, were much more potent than 2 (and 1) in both of the above assays (up
to ca. 200-fold). However, only compounds with a hydroxyl or an aceta
te group at C-4 displayed significantly reduced acute toxicity and sed
ative properties relative to those of 1. Importantly, the diminishment
of toxicity and sedation were not the result of a lack of brain penet
ration as both 2 and the corresponding ketone (3,3-dimethyl-3,4-dihydr
o-3H-isoquinolin-4-one N-oxide) achieved equal or greater brain levels
than those of 1 when administered to rats ip.